Bio-Rad Laboratories v. GigaGen: Microfluidic Patent Case Dismissed With Prejudice
Bio-Rad Laboratories and the University of Chicago filed suit against GigaGen, Inc. in the California Eastern District Court over two patents covering microfluidic plug-based reaction systems. Both causes of action were dismissed with prejudice after 376 days, with each party bearing its own costs and attorneys' fees.
Bio-Rad and GigaGen reach stipulated end to microfluidic IP dispute
On 16 November 2022, Bio-Rad Laboratories, Inc. and the University of Chicago filed suit against GigaGen, Inc. in the California Eastern District Court, asserting infringement of two patents: US8304193B2, covering methods for conducting reactions involving biological molecules in plugs in a microfluidic system, and US8329407B2, covering methods for conducting autocatalytic reactions in plugs in a microfluidic system. GigaGen did not assert any counterclaims in the proceeding.
The recorded Basis of Termination is 'Dismissed with Prejudice.' The docket order reflects a stipulation agreed by all parties — Bio-Rad, the University of Chicago, and GigaGen — through which both the First and Second Causes of Action were dismissed with prejudice, and each party agreed to bear its own costs and attorneys' fees, subject to court approval. The specific terms underlying the parties' agreement to stipulate are not disclosed in the available record.
The case closed on 27 November 2023, approximately 376 days after filing. The absence of any counterclaims from GigaGen and the relatively contained litigation timeline may suggest the dispute resolved before substantive merits adjudication, though what drove the parties to stipulate dismissal is not disclosed in the public record.
See Complete Case & Patent Analysis →Filing to Dismissed with Prejudice in 376 days
from filing to dismissal — slightly above median for early IP resolutions
US8304193B2 & US8329407B2 — microfluidic plug-based reaction methods
Any company developing or commercialising microfluidic systems that use plug or droplet formats for biological reactions — including single-cell sequencing, droplet PCR, antibody discovery, or microfluidic enzyme assays — should assess freedom-to-operate against US8304193B2 and US8329407B2. Both patents exited this litigation unadjudicated, with full enforcement potential intact. Co-ownership by Bio-Rad and the University of Chicago means enforcement rights are held by an active commercial plaintiff.
Official order — verbatim text
The stipulation records an agreed dismissal with prejudice of both infringement causes of action, with no counterclaims having been filed by GigaGen. The order does not reflect any court determination on validity, infringement, or claim construction — the dismissal is procedurally final but substantively silent, leaving the patents' technical merits unadjudicated.
Dismissed with prejudice: what the stipulated resolution means for both parties
Dismissal with prejudice ends the litigation permanently
A dismissal with prejudice is a final disposition on the merits for procedural purposes — it bars the plaintiffs from re-filing the same claims against GigaGen in any future action. Here, the dismissal arose from a stipulation agreed by all parties, meaning the court entered it on the basis of mutual consent rather than a contested ruling. The specific terms prompting the stipulation are not disclosed in the available record.
Final — no re-filing permittedBio-Rad and University of Chicago cannot reassert these claims against GigaGen
By stipulating to dismissal with prejudice, Bio-Rad and the University of Chicago relinquish the right to pursue these specific infringement claims against GigaGen under US8304193B2 and US8329407B2. The patents themselves remain in force and enforceable against other parties. The underlying reasons for the plaintiffs' agreement to the dismissal are not disclosed in the public record.
Patents remain enforceable vs. othersGigaGen exits litigation without a merits adjudication
GigaGen, Inc. obtains a final end to this litigation without having asserted counterclaims or obtained a court ruling on validity or infringement. The dismissal with prejudice provides finality against these specific claims by these plaintiffs, though no judicial finding on the substantive patent questions was recorded. Each party bears its own costs and attorneys' fees.
No validity ruling enteredMicrofluidic IP landscape: patents intact, sector exposure remains
US8304193B2 and US8329407B2 survive this litigation with no adverse validity or enforceability ruling. Companies operating in microfluidic droplet and plug-based biology platforms — including drug discovery, genomics, and single-cell analysis workflows — should note that these patents remain available for assertion against third parties. The absence of a merits ruling preserves the patents' full enforcement potential.
Patents enforceable vs. third partiesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bio-Rad Laboratories | Company | /Search in Eureka ↗ |
| Defendant | GigaGen, Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Derek C. Walter | Attorney | Counsel for Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Plaintiff counsel | Edward Robert Reines | Attorney | Counsel for Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Plaintiff counsel | Gregg Thomas Stephenson | Attorney | Counsel for Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Plaintiff law firm | Weil Gotshal & Manages, LLP | Law Firm | Representing Bio-Rad LaboratoriesSearch in Eureka ↗ |
| Defendant counsel | Daralyn J. Durie | Attorney | Counsel for GigaGen, Inc.Search in Eureka ↗ |
| Defendant counsel | Eugene Novikov | Attorney | Counsel for GigaGen, Inc.Search in Eureka ↗ |
| Defendant counsel | Jennifer J. Shih | Attorney | Counsel for GigaGen, Inc.Search in Eureka ↗ |
| Defendant counsel | Joyce C. Li | Attorney | Counsel for GigaGen, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael A. Jacobs | Attorney | Counsel for GigaGen, Inc.Search in Eureka ↗ |
| Defendant counsel | Nate Tan | Attorney | Counsel for GigaGen, Inc.Search in Eureka ↗ |
| Defendant counsel | Nicholas Rylan Fung | Attorney | Counsel for GigaGen, Inc.Search in Eureka ↗ |
| Defendant law firm | Grifols Shared Services, North America | Law Firm | Representing GigaGen, Inc.Search in Eureka ↗ |
| Defendant law firm | Morrison & Foerster LLP | Law Firm | Representing GigaGen, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Eastern District CourtSearch in Eureka ↗ |
R&D signals in the microfluidic plug-reaction IP space
Forward-looking patent and innovation intelligence derived from Bio-Rad and GigaGen's activity in microfluidic droplet biology and plug-based reaction technologies.
Bio-Rad's microfluidic IP portfolio extends well beyond these two patents
Bio-Rad Laboratories holds a substantial portfolio in droplet and plug-based microfluidics, anchored partly through its acquisition of RainDance Technologies. Tracking their filing activity around plug chemistry, emulsion PCR, and droplet digital biology reveals the breadth of enforcement risk for platform developers working in adjacent spaces.
Portfolio depth — Bio-RadPlug-based microfluidic reaction patents: a crowded and contested space
Patent filing trends in plug and droplet microfluidics have accelerated alongside single-cell genomics and high-throughput screening markets. Mapping the claim landscape around autocatalytic and biological plug reactions — the exact domain of the asserted patents — helps identify white space and freedom-to-operate corridors for next-generation platform design.
Filing trends — microfluidicsGigaGen's patent position in microfluidic antibody discovery
GigaGen, Inc. focuses on immune repertoire analysis and recombinant polyclonal antibody production. Assessing its own patent filings in microfluidic single-cell capture and droplet-based library construction reveals how it is building — or not building — defensive IP against enforcement actions from entrenched platform holders like Bio-Rad.
Defensive IP — GigaGenAdjacent innovation opportunities near plug-reaction microfluidic claims
The claim scope of US8304193B2 and US8329407B2 centres on plug-format reactions in microfluidic channels. Adjacent white space may exist in continuous-flow formats, digital microfluidics (electrowetting), and organ-on-chip architectures that achieve similar biological assay goals through structurally distinct mechanisms — potentially outside the asserted claims.
White space — adjacent formatsSimilar microfluidic patent infringement cases in US district courts
Browse comparable patent infringement disputes involving microfluidic systems and droplet-based biological methods litigated in California and other US district courts.
What this case signals for the microfluidics IP landscape
Two foundational microfluidic plug-reaction patents survive litigation intact — with full enforcement potential against the broader sector.
Both microfluidic patents remain enforceable with no adverse ruling
US8304193B2 and US8329407B2 exited this litigation without any validity or infringement finding. Competitors in plug-based microfluidic workflows — single-cell sequencing, droplet PCR, antibody discovery — face the same enforcement risk from these patents as before the suit was filed.
No counterclaims filed: GigaGen's defensive IP posture in microfluidics
GigaGen did not assert any counterclaims, including invalidity challenges, during the litigation. This suggests either a limited defensive patent portfolio in this domain or a strategic decision to avoid escalation. Competitors monitoring GigaGen's IP posture in immune repertoire and microfluidic platforms should track its filing activity closely.
Bio-Rad v GigaGen — key questions answered
Bio-Rad Laboratories and the University of Chicago asserted two patents: US8304193B2, covering methods for conducting reactions involving biological molecules in plugs in a microfluidic system, and US8329407B2, covering methods for conducting autocatalytic reactions in plugs in a microfluidic system. GigaGen did not assert any counterclaims.
The case ended via a stipulated dismissal with prejudice, agreed by all parties, with each side bearing its own costs and attorneys' fees. Dismissal with prejudice is final — Bio-Rad and the University of Chicago cannot re-file these specific claims against GigaGen. However, no court ruled on validity or infringement; the patents remain enforceable against other parties.
No. Neither patent was adjudicated on the merits. The case ended by stipulated dismissal with prejudice before any validity or infringement ruling was entered. Both patents exit the litigation with their legal presumption of validity fully intact.
The University of Chicago is named as a co-plaintiff, consistent with it being a co-owner or co-assignee of the asserted patents. The specific ownership or licensing arrangement is not detailed in the available public record. Co-ownership by an academic institution typically requires joint participation in enforcement actions.
The dismissal with prejudice binds only Bio-Rad, the University of Chicago, and GigaGen with respect to these specific claims. It does not restrict enforcement against third parties. US8304193B2 and US8329407B2 remain fully enforceable, and any company operating plug-based microfluidic biological or autocatalytic reaction platforms should consider conducting a freedom-to-operate analysis against these patents.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.